Genetic testing for immunotherapies

_________

Oncologica is a leading laboratory in genetic cancer testing.
We help patients and oncologists to get the maximum benefit from new cancer treatments.

Powerful therapies with high specificity and low toxicity.

Immunotherapy doesn’t work the same for everyone: in some patients it appears to work incredibility well, completely destroying tumours, for other patients, the response can be less dramatic.

Before assessing whether the patient is eligible for these new treatment options it is therefore essential to first identify whether the patient will benefit from from such therapy.

A comprehensive DNA test to precisely identify patient’s eligible for immunotherapy

Immunofocus PD-L1, MMR and TMB testing can be applied to the routine tumour biopsy to precisely identify patients who can derive benefit from immunotherapy drugs.

The development of cancer is associated with the acquisition of DNA mutations which also results in the expression of mutated proteins on the surface of cancer cells called neoantigens.

Neoantigens are recognised by the body as foreign leading to an attack on the cancer cells by the patient’s own immune cells.

Limits of
Immunotherapy

Immunotherapy doesn’t work for everyone: in some patients it appears to work incredibility well, completely destroying tumours even after they have begun to spread around the body, but for other patients the response can be less dramatic.

The different responses to immunotherapy reflect differences in the genetic profile and immunoprofile of each cancer patient.

How can Oncologica’s genomic profiling be helpful for decisions on immunotherapy?

Oncologica now performs a series of genetic and immunoprofiling tests which helps identify those patients most likely to benefit from immunotherapy.

Immunofocus MMR and Immunofocus TMB combined with Oncofocus identify cellular changes such as defects in DNA damage repair and immune signalling that flag up tumours sensitive to immunotherapy. Immunofocus TMB provides an assessment of global DNA mutation burden and asssociated neoantigens.

Patients who score positive in these four tests are strong candidates for immunotherapy.

Oncologica® is a leading precision oncology certified laboratory based in the prestigious Chesterford Research Park, Cambridge, UK.

Since 2015 we have been helping oncologists and patients every day to get the maximum benefit from new advanced genetic profiling techniques for the treatment of cancer.